Metadata

Dataset ID: 17
Back to List

Study Design
Study Design Background The study provides evidence that SYRO plus MET has a synergistic effect on tumor growth inhibition in both 4T1 and TS/A experimental models
Study Description SYRO plus MET, this radiotracer could be potentially used as a biomarker for the early detection of therapy response
Study Type preclinical
Study Subtype in vivo, ex vivo
Publication
Paper Linked yes
Paper Title Evaluating [18F]FDG and [18F]FLT Radiotracers as Biomarkers of Response for Combined Therapy Outcome in Triple-Negative and Estrogen-Receptor-Positive Breast Cancer models
Paper Authors Rainone P, Valtorta S, Villa C, Todde S, Cadamuro M, Bertoli G, Conconi D, Lavitrano M, Moresco RM
Affiliation University of Milano - Bicocca
Paper Journal International Journal of Molecular Sciences
Paper Year 2023
Paper Doi https://doi.org/10.3390/ijms241814124
Open Access yes
Updated Year 2024
Study Component
Multi Modality Images yes
Imaging Modality PET/CT
Radiation yes
Imaging Coverage whole body
Imaging Target tumor
Dataset Information
Institution IBSBC-CNR
Pi Prof. Moresco Rosa Maria
Country Of Institution Italy
Imaging Facility Laboratory of preclinical molecular imaging
Euro Bio Imaging Node MMMI
Country Of Imaging Facility Italy
Funding yes
Funding Agency MOLIM ONCOBRAIN LAB—Innovative methods of molecular imaging for the study of oncological and neurodegenerative diseases, AIRC
Grant Number 2017-NAZ-0146/A, grant n.21635
Dataset Access limited
Duo Data Use Permission DUO:0000042
Duo Data Use Modifier DUO:0000046
Duo Investigation DUO:0000040
Contact Person paolo.rainone@unimib.it
In Vivo Experimental Parameters
Number Of Groups 6
Types Of Groups control, cisplatin, MET, cisplatin plus MET, SYRO, and SYRO plus MET
Overall Sample Size 57
Disease Model breast cancer
Organ Or Tissue mammary gland
Sample Size For Each Group 5 o 4
Randomization yes, when tumors were palpable, the animals inoculated with 4T1 or TS/A were randomly assigned
Blinding no
Statistical Methods Student’s t-test
Species Mice
Strain Balb/c
Immune Status immunecompetent
Sex female
Age 7-8 weeks
Age At Start Experiment 8 weeks
Age At Scanning Experiment S 56 and 63 days
Weight 24-26 g
Genotype n/a
Genetic Manipulation n/a
Gene n/a
Source Of Animals Charles River Laboratories, Italy
Experimental Procedures
Pharmacological Procedures Intervention And Control yes
Pharmacological Drug metformin, syrosingopine, cisplatin
Company Sigma Aldrich
Drug Dose MET 250 mg/kg, SYRO 7.5 mg/kg, cisplatin 3 mg/kg
Site Route Of Administration intraperitoneal
Frequency Of Administration MET daily, SYRO three times for week, cisplatin twice a week
Vehicle Or Carrier Solution Formulation All drugs dissolved in saline, except SYRO that was dissolved in DMSO (10% in sterile water)
Blood Sampling no
Surgical Procedures Including Sham Surgery no
Pathogen Infection Intervention And Control no
Analgesic Plan To Relieve Pain Suffering And Distress no
Anesthesia For Imaging yes
Anesthesia Type gas
Duration 20
Anesthesia Drugs isoflurane
Anesthesia Dose 2%
Euthanasia yes
Method anesthesia
Histology yes
Tissues Collected Post Euthanasia tumor
Timing Of Collection end of study
Imaging yes
Frequency Of Imaging Single scan
Timing Of Imaging t0 and after 7 days of the treatment
Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule yes
Contrast Agent Commercial Drug [18F]FDG, [18F]FLT
Contrast Agent Chemical Drug 18F-fluorodeoxyglucose (FDG), 18F-fluorothymidine (FLT)
Contrast Agent Dose 4.67 ± 0.3 MBq
Injection Volume 0.05 - 0.1 ml
Route Of Administration intravenous
Cell Lines yes
Cell Line 4T1, TS/A
Provenance TS/A (Sigma-Aldrich Inc., St. Louis, MO, USA), 4T1 (ATCC)
Image Acquisition
Instrument Vendor Molecubes
Instrument Type β-cube, X-cube
Instrument Specifics FOV size for PET 130X72 mm, FOV size for CT 37X65 mm
Image Acquisition Parameters CT scan (exam duration: 4 min, X-Ray beam duration: 90 s, kVp: 40, current:400 A, rotation time: 60 s, and angular views: 960), PET scanner for a 20 min static acquisition
Correction decay correction (PET)
Raw Data yes
Image Correlation
Image Type Processed images (reconstructed PET and CT data)
Image Scale SUV for PET
Format Compression DICOM
Dimensions 3D
Overall Number Of Images 36
Field Of View Abdominal
Dimension Extents 192x192x384
Pixel Voxel Size Description 0.4x0.4x0.4
Image Processing Methods Image reconstruction
Image Reconstruction Algorithm OSEM
Quality Control n/a
Image Smoothing Or Filtering Algorithm n/a
Image Registration Algorithm n/a
Ai Enhanced Algorithm yes
Analyzed Data
Data Used For Analysis SUV, volume measurements
Status complete
Ontology Terms
Ncit Imaging NCIT:C103512
Doid DOID:1612
Ncit Anatomy NCIT:C12367
Ncit Species NCIT:C14238
Ncit Strain NCIT:C37357
Chebi Pharmaco CHEBI:6801,CHEBI:32175,CHEBI:27899
Chebi Anesthesia CHEBI:6015
Chebi Contrast Agent Commercial Name CHEBI:49134,NCIT:C49093
Chebi Contrast Agent Chemical Name CHEBI:49134,NCIT:C49093
Clo CLO:0001401,CLO:0009405
Back to List